Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2010-07-19 Investor Presentation
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT Presentation to Australian Investors 22 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed investor presentation from LCT, describing their products, clinical trials, market data, and commercialization milestones. It includes forward-looking statements, product pipeline, clinical trial phases, market capitalization, and strategic plans. There is no indication that this is a formal regulatory filing like an annual or quarterly report, audit report, or earnings release. The content is typical of an investor presentation aimed at providing comprehensive information about the company's business, technology, and financial outlook to investors. Therefore, the document best fits the category of an Investor Presentation (IP).
2010-07-19 English
Section 708A (5) (e) Cleansing Statement 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 15 July 2010 regarding relief under Section 708A(5)(e) of the Corporations Act 2001. It details the issuance of shares to sophisticated investors without disclosure under Part 6D.2 of the Corporations Act and confirms compliance with relevant provisions. The content is a regulatory notice about a capital raising event and legal compliance, not a full financial report or detailed financing update. Given the short length (1203 characters) and the nature of the announcement, it fits best under Capital/Financing Update (CAP) as it relates to share issuance and capital raising disclosures.
2010-07-14 English
LCT reports consistent benefit in DIABECELL NZ Trial 3 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a company announcement reporting interim clinical trial results for a medical product (DIABECELL) developed by Living Cell Technologies Limited. It provides detailed updates on patient outcomes, safety, and future plans for clinical trials. The content is focused on clinical trial progress and product development rather than financial results, regulatory filings, or shareholder information. There is no indication that this is a financial report, earnings release, regulatory filing, or any other formal financial or governance document. It is a company announcement about clinical trial progress and product development, which does not fit into the predefined financial or regulatory filing categories. Therefore, the best fit is Regulatory Filings (RNS) as a general category for miscellaneous company announcements that do not fit other specific categories.
2010-07-12 English
Appendix 3B 7 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, issue price, purpose, and quotation application to the ASX (Australian Securities Exchange). It includes sections on the securities issued, underwriting, quotation agreement, and compliance warranties. The document is a formal announcement related to a new share issue and application for quotation of additional securities, consistent with regulatory requirements for capital raising disclosures. It does not contain financial statements, management discussion, or audit information, nor is it a report or transcript. It is clearly an announcement of a capital/financing activity, specifically a new share issue and quotation application. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9982 characters) and content confirm it is a full announcement, not a brief notice or report publication announcement.
2010-07-12 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares and options held before and after the change, nature of the change (expired options), and dates. This is a report of personal share transactions by a company director. The document length is 3080 characters, which is consistent with a detailed notice of director dealings rather than a brief announcement or a full financial report. Therefore, the document fits the definition of Director's Dealing (DIRS).
2010-07-06 English
Appendix 3B 7 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, issue price, purpose of the issue, and quotation application to the ASX. It references ASX rules and compliance warranties related to the quotation of securities. The content is focused on announcing and providing details about a new share issue and the application for quotation of these additional securities on the stock exchange. There are no financial statements, management discussion, or audit information present. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues and related capital changes.
2010-07-01 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.